Citigroup Maintains Buy on Bio-Techne, Lowers Price Target to $70
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Patrick Donnelly maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $80 to $70.
Citigroup analyst Patrick Donnelly maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $80 to $70.